Skip to main content

Published locations for RELAZA2: MRD-guided azacitidine reduces relapse risk in MDS and AML

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. RELAZA2: MRD-guided azacitidine reduces relapse risk in MDS and AML

User login

  • Reset your password
  • /content/relaza2-mrd-guided-azacitidine-reduces-relapse-risk-mds-and-aml
  • /hematologynews/article/156641/myelodysplastic-syndrome/relaza2-mrd-guided-azacitidine-reduces
  • /oncologypractice/article/156641/myelodysplastic-syndrome/relaza2-mrd-guided-azacitidine-reduces
  • /hematology-oncology/article/156641/myelodysplastic-syndrome/relaza2-mrd-guided-azacitidine-reduces